The newest publication supported by Manysmart, The potential of adoptive transfer of γ9δ2 T cells to enhance blinatumomab’s antitumor activity against B-cell malignancy, now comes to Scientific Reports.
It strongly suggested human γ9δ2 T cells combined with CD19BiTE may provide an efficient therapy for CD19-positive B-cell cancers.
In other words, the technology of γ9δ2 T cell expansion from Manysmart fully fits the requirement of experiments and tests and the expanded γ9δ2 T cells still show a valuable anti-tumor property.
